Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00826046
Expanded Access Status : No longer available
First Posted : January 21, 2009
Last Update Posted : March 9, 2020
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd. ( Mesoblast, Inc. )

Brief Summary:
This protocol allows for the treatment of patients, male and female, between the ages of 18 years and 70 years. Patients must have failed to respond to steroid treatment for Grade C-D acute GVHD.

Condition or disease Intervention/treatment
Graft-Versus-Host Disease Drug: Prochymal®

Detailed Description:

This is a treatment protocol to provide patients who have failed steroid treatment for acute GVHD expanded access of Prochymal. It is anticipated that a maximum of 10 patients per month for a total of 120 patients per year will be treated according to this protocol.

Patients will be treated with Prochymal twice per week at a dose of 2 x 106 human mesenchymal stem cell (hMSC)/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.

Layout table for study information
Study Type : Expanded Access
Official Title: Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD



Intervention Details:
  • Drug: Prochymal®
    Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
    Other Name: Ex-vivo Cultured Adult Human Mesenchymal Stem Cells

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients must be 18 years to 70 years of age, inclusive.
  • Biopsy confirmation of GVHD is strongly recommended, to exclude patients presenting with diarrhea or abnormal liver function tests caused by infection.
  • Patients must have failed to respond to steroid treatment (methylprednisolone [≥1mg/kg/day] or equivalent) for Grades C-D acute GVHD.
  • Prochymal must be administered not longer than 14 days after the initiation of systemic steroid therapy for acute GVHD.
  • Prochymal must be administered either before or at the same time any additional GVHD therapy is administered
  • Patients must have an adequate renal function as defined by Cockcroft-Gault equation:Calculated creatinine clearance (CrCl) > 30 mL/min
  • Patients who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception.

Exclusion Criteria:

  • Patient has stage 3 or 4 liver GVHD, bilirubin >6 mg/dl.
  • Patient has stage 4 GI-GVHD.
  • Patient has any underlying or current medical condition that would interfere with the evaluation of the patient including uncontrolled infection, sepsis, organ failure, etc or any medical condition that has a high probability of causing death in less than 30 days.
  • Patient may not receive any other investigational agent (not approved by the FDA for any indication) concurrently for the duration of the protocol.
  • Patient has evidence of a pulmonary infiltrate or diffuse alveolar hemorrhage and must not be likely to require more than 2 liters of oxygen via face mask or an estimated fractional inspired oxygen concentration (FiO2) of 28% via other delivery methods in order to sustain an O2 saturation of 92% during the next 3 days.
  • Patient has a known allergy to bovine or porcine products
  • Patient has a medical history of a solid tumor disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00826046


Locations
Layout table for location information
United States, Indiana
Indiana BMT
Beech Grove, Indiana, United States, 46107
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02284
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Mesoblast, Inc.
Investigators
Layout table for investigator information
Study Director: Mahboob Rahman, MD Mesoblast, Inc.
Layout table for additonal information
Responsible Party: Mesoblast, Inc.
ClinicalTrials.gov Identifier: NCT00826046    
Other Study ID Numbers: 276
First Posted: January 21, 2009    Key Record Dates
Last Update Posted: March 9, 2020
Last Verified: March 2020
Keywords provided by Mesoblast, Ltd. ( Mesoblast, Inc. ):
GVHD
Prochymal
Graft vs Host Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases